Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells

Journal of Hepatology

Volumn 57, Issue 1, 2012, Pages 108-115

  Blivet Van Eggelpoël, Marie José ^a,b   Chettouh, Hamza ^a,b   Fartoux, Laetitia ^a,b,c   Aoudjehane, Lynda ^a,b   Barbu, Véronique ^a,b,c   Rey, Colette ^a,b   Priam, Sabrina ^a,b   Housset, Chantal ^a,b   Rosmorduc, Olivier ^a,b,c   Desbois Mouthon, Christèle ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Amphiregulin; EGFR; ERK; Gefitinib; HER 3 ErbB 3

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SORAFENIB; STAT3 PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOPROTEINS; HEP G2 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MIDDLE AGED; PYRIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862692712     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.02.019     Document Type: Article

References (30)

1. Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009;25:186-194.
2. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010;80:550-560.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
5. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-3140.
6. Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, et al. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res 2009;69:6515-6521.
7. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 2008;7:3519-3526.
8. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, et al. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res 2009;15:5820-5828.
9. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 2009;52:79-87.
10. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, et al. Role of RAF/ MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 2009;220:214-221.
11. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 2011;55:1041-1048.
12. Zhu AX. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:663-672.
13. Siegel AB, Olsen SK, Magun A, Brown Jr RS. Sorafenib: where do we go from here? Hepatology 2010;52:360-369.
14. Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 2007;27:174-185.
15. Hsieh SY, He JR, Hsu CY, Chen WJ, Bera R, Lin KY, et al. Neuregulin/ erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma. Hepatology 2011;53:504-516.
16. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008;7:2589-2598.
17. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 2008;7: 3499-3508.
18. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël M, Fartoux L, Venot C, Bladt F, et al. IGF-1R inhibition induces a resistance mechanism via the EGFR/HER3/AKT signaling pathway: rational basis for co-targeting IGF-1R and EGFR in hepatocellular carcinoma. Clin Cancer Res 2009;15: 5445-5456.
19. Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 2010;16:4990-5001.
20. Podevin P, Carpentier A, Pene V, Aoudjehane L, Carriere M, Zaidi S, et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 2010;139:1355-1364.
21. Desbois-Mouthon C, Danan C, Amselem S, Blivet-Van Eggelpoel MJ, Sert- Langeron C, Goossens M, et al. Severe resistance to insulin and insulin-like growth factor-I in cells from a patient with leprechaunism as a result of two mutations in the tyrosine kinase domain of the insulin receptor. Metabolism 1996;45:1493-1500.
22. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-11858.
23. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn Jr PA, et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007;6:1683-1691.
24. Zhu AX. Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? BMC Med 2009;7:42.
25. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
26. Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, Calabrese C, et al. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res 2010;70:4499-4508.
27. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, et al. Skin tumors induced by sorafenib: paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53 and TGFBR1. Clin Cancer Res 2012;18:263-272.
28. Hickinson DM, Marshall GB, Beran GJ, Varella-Garcia M, Mills EA, South MC, et al. Identification of biomarkers inhuman head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin Transl Sci 2009;2:183-192.
29. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008;14: 6963-6973.
30. Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, et al. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Cancer 2011;117:143-151.